Show simple item record

dc.contributor.authorSchoenmakers, Erik
dc.contributor.authorChatterjee, Krishna
dc.date.accessioned2022-01-28T14:47:02Z
dc.date.available2022-01-28T14:47:02Z
dc.date.issued2021-11-29
dc.identifier.issn1661-6596
dc.identifier.other34884733
dc.identifier.otherPMC8658020
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/333110
dc.description.abstractSelenium, a trace element fundamental to human health, is incorporated as the amino acid selenocysteine (Sec) into more than 25 proteins, referred to as selenoproteins. Human mutations in SECISBP2, SEPSECS and TRU-TCA1-1, three genes essential in the selenocysteine incorporation pathway, affect the expression of most if not all selenoproteins. Systemic selenoprotein deficiency results in a complex, multifactorial disorder, reflecting loss of selenoprotein function in specific tissues and/or long-term impaired selenoenzyme-mediated defence against oxidative and endoplasmic reticulum stress. SEPSECS mutations are associated with a predominantly neurological phenotype with progressive cerebello-cerebral atrophy. Selenoprotein deficiency due to SECISBP2 and TRU-TCA1-1 defects are characterized by abnormal circulating thyroid hormones due to lack of Sec-containing deiodinases, low serum selenium levels (low SELENOP, GPX3), with additional features (myopathy due to low SELENON; photosensitivity, hearing loss, increased adipose mass and function due to reduced antioxidant and endoplasmic reticulum stress defence) in SECISBP2 cases. Antioxidant therapy ameliorates oxidative damage in cells and tissues of patients, but its longer term benefits remain undefined. Ongoing surveillance of patients enables ascertainment of additional phenotypes which may provide further insights into the role of selenoproteins in human biological processes.
dc.description.sponsorshipNIHR Cambridge Biomedical Research Centre
dc.languageeng
dc.publisherMDPI AG
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourcenlmid: 101092791
dc.sourceessn: 1422-0067
dc.subjectSelenium
dc.subjectSepsecs
dc.subjectSecisbp2
dc.subjectSelenoprotein Deficiency
dc.subjectSec-trna[ser]sec
dc.subjectHumans
dc.subjectAmino Acid Metabolism, Inborn Errors
dc.subjectAmino Acyl-tRNA Synthetases
dc.subjectRNA-Binding Proteins
dc.subjectRNA, Transfer, Amino Acid-Specific
dc.subjectMutation
dc.subjectSelenoproteins
dc.titleHuman Genetic Disorders Resulting in Systemic Selenoprotein Deficiency.
dc.typeArticle
dc.date.updated2022-01-28T14:47:01Z
prism.issueIdentifier23
prism.publicationNameInt J Mol Sci
prism.volume22
dc.identifier.doi10.17863/CAM.80534
dcterms.dateAccepted2021-11-27
rioxxterms.versionofrecord10.3390/ijms222312927
rioxxterms.versionVoR
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0/
dc.contributor.orcidSchoenmakers, Erik [0000-0003-0674-8282]
dc.contributor.orcidChatterjee, Krishna [0000-0002-2654-8854]
dc.identifier.eissn1422-0067
pubs.funder-project-idWellcome Trust (210755/Z/18/Z)
cam.issuedOnline2021-11-29


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International